%0 Journal Article
%T Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study
%A Wenjing Zhou
%A Karin Jirstr£¿m
%A Christine Johansson
%A Rose-Marie Amini
%A Carl Blomqvist
%A Olorunsola Agbaje
%A Fredrik W£¿rnberg
%J BMC Cancer
%D 2010
%I BioMed Central
%R 10.1186/1471-2407-10-653
%X All 458 women with a primary DCIS diagnosed between 1986 and 2004, in Uppland and V£¿stmanland, Sweden were included. TMA blocks were constructed. To classify the DCIS tumors, we used immunohistochemical (IHC) markers (estrogen-, progesterone-, HER2, cytokeratin 5/6 and epidermal growth factor receptor) as a surrogate for the gene expression profiling. The association with prognosis was examined for basal-like DCIS and other subtypes using Kaplan-Meier survival analyses and Cox proportional hazards regression models.IHC data were complete for 392 women. Thirty-two were basal-like (8.2%), 351 were luminal or HER2-positive (89.5%) and 9 unclassified (2.3%). Seventy-six women had a local recurrence of which 34 were invasive. Another 3 women had general metastases as first event. Basal-like DCIS showed a higher risk of local recurrence and invasive recurrence 1.8 (Confidence interval (CI) 95%, 0.8-4.2) and 1.9 (0.7-5.1), respectively. However, the difference was not statistically significant. Also, no statistically significant increased risk was seen for triple-negative or high grade DCIS.Basal-like DCIS showed about a doubled, however not statistically significant risk for local recurrence and developing invasive cancer compared with the other molecular subtypes. Molecular subtyping was a better prognostic parameter than histopathological grade.Increased use of screening mammography, beginning in the early 1980 s, has resulted in a dramatic increase in detection of ductal carcinoma in situ (DCIS). DCIS is a pre-invasive disease with a clinically and molecularly heterogeneous presentation that poses a major challenge in both diagnosis and treatment [1-3]. A clinically accepted classification system predicting prognosis is still missing.Recently, the idea of using molecular subtyping to predict the prognosis of invasive breast cancer has been widely accepted [4-8]. The introduction of high-throughput DNA microarray technologies marked an entirely new era of genome-wide ap
%U http://www.biomedcentral.com/1471-2407/10/653